

KinLET Trial

A Phase I Trial to Determine the Dose and Evaluate the PK of ¹⁷⁷Lu-edotreotide Targeted Radiopharmaceutical Therapy in Pediatric Participants with SSTR-positive Tumors

What is it looking at?

Determining the dose and safety of ¹⁷⁷Lu-edotreotide and evaluate how it moves through the body (pharmacokinetics) in pediatric patients with SSTR-positive tumors.

What is ¹⁷⁷Lu-edotreotide?

A radiopharmaceutical that targets specific receptors on certain tumor types.

What is targeted radiopharmaceutical therapy (RPT)?

Targeted RPT aims to damage the tumor cells without attacking healthy cells. RPT consists of two components: a targeting portion and a radioactive portion. The targeting portion specifically binds to certain targets (or receptors) found on the tumor surface. The radioactive portion releases energy that can potentially help destroy cancer cells (therapy).

What is SSTR?

Somatostatin receptor (SSTR) is a protein that sits on the outside of cells, which receives a signal once it binds to its specific target. It is highly expressed on the tumor types being explored in this trial. There are several methods to confirm SSTR expression in tumors cells which can be checked in both tumor samples and by imaging.

What cancer types are being studied?

- Neuroendocrine Tumors (NETs)
- Neuroblastoma
- Pheochromocytoma / paraganglioma
- CNS tumors: meningioma, medulloblastoma, high/low grade glioma
- Lymphoma
- Rhabdomyosarcoma
- Peripheral primitive neuroectodermal tumors pPNETS (Ewing family of sarcomas)
- Gastrointestinal sarcoma tumor (GIST)

What does Phase I mean?

A phase I clinical trial involves a small number of patients to determine what the best dose is and how it works in the body.

Additional details

- Participants aged 24 months and older but younger than 18 years
- Confirmed SSTR expression in tumor sample
- Somatostatin receptor positive (SSTR-positive) disease confirmed by SSTR imaging
- Tumor which is relapsed or is refractory to at least one line of previous therapy

For more information go to [www.clinicaltrials.gov](https://www.clinicaltrials.gov/ct2/show/NCT06441331), NCT06441331.